Research output per year
Research output per year
Personal profile
About
Dr. Heather Brooks is an oncologist in Blacksburg, Virginia and is affiliated with multiple hospitals in the area, including LewisGale Medical Center and Salem Veterans Affairs Medical Center. She received her medical degree from Eastern Virginia Medical School.
Education/Academic qualification
Fellowship, Hematology/Oncology, University of Texas Health Science Center at Houston
2008 → 2011
Residency, Internal Medicine, University of Virginia
2005 → 2008
MD, Eastern Virginia Medical School
… → 2005
Disciplines
- Medicine and Health Sciences
- Oncology
Research output
- 11 Article
-
Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.
Andorsky, D., Coleman, M., Yacoub, A., Melear, J. M., Brooks, H. D., Fanning, S. R., Kolibaba, K. S., Lansigan, F., Reynolds, C., Li, J., Liu, D., Llorente, M., Ricker, J. L. & Sharman, J. P., Jun 1 2018, In: Journal of Clinical Oncology. 36Research output: Contribution to journal › Article › peer-review
-
Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).
Andorsky, D. J., Yacoub, A., Melear, J. M., Coleman, M., Kolibaba, K. S., Brooks, H. D., Bitran, J. D., Fanning, S. R., Lansigan, F., Ricker, J. L., Foon, K. A., Liu, D., Llorente, M., Li, J. & Sharman, J. P., May 30 2017, In: Journal of Clinical Oncology. 35Research output: Contribution to journal › Article › peer-review
-
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Sharman, J. P., Farber, C. M., Mahadevan, D., Schreeder, M. T., Brooks, H. D., Kolibaba, K. S., Fanning, S., Klein, L., Greenwald, D. R., Sportelli, P., Miskin, H. P., Weiss, M. S. & Burke, J. M., Feb 1 2017, In: British Journal of Haematology. 176, 3Research output: Contribution to journal › Article › peer-review
-
MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
Andorsky, D. J., Yacoub, A., Bitran, J. D., Melear, J., Brooks, H. D., Foon, K. A., Rizvi, S., Llorente, M., Li, J. & Sharman, J. P., Dec 2 2016, In: Blood. 128, 22Research output: Contribution to journal › Article › peer-review
-
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial
Sharman, J. P., Farber, C. M., Mahadevan, D., Schreeder, M. T., Brooks, H. D., Kolibaba, K. S., Fanning, S. R., Klein, L. M., Sportelli, P., Miskin, H. P., Weiss, M. S. & Greenwald, D. R., Dec 6 2014, In: Blood. 124, 21Research output: Contribution to journal › Article › peer-review